Quinoline‑Induced Hemolysis

What is Quinoline‑induced hemolysis?

Hemolysis is the premature destruction of red blood cells (RBCs), which leads to a drop in hemoglobin and can cause anemia, jaundice, and organ damage. Quinoline‑induced hemolysis refers specifically to RBC breakdown that occurs after exposure to drugs or chemicals that contain a quinoline ring structure. Quinoline derivatives are used in several antimalarial, anti‑inflammatory, and antibacterial agents. In susceptible individuals—most notably those with the inherited enzyme defect glucose‑6‑phosphate dehydrogenase (G6PD) deficiency—the drug can trigger oxidative stress that the red cells cannot compensate for, resulting in rapid cell lysis.

While many people tolerate quinoline‑based medicines without trouble, those with G6PD deficiency or certain other risk factors may develop hemolysis within hours to days of taking the medication. Prompt recognition is essential because severe hemolysis can lead to acute kidney injury, severe anemia, or even death if left untreated.

Common Causes

The following are the most frequent drugs, chemicals, and conditions that have been documented to cause quinoline‑induced hemolysis:

• Primaquine – an antimalarial used for radical cure of Plasmodium vivax and P. ovale infections.
• Chloroquine and hydroxychloroquine – antimalarial and anti‑inflammatory agents; hydroxychloroquine is also used for lupus and rheumatoid arthritis.
• Quinine – historically used for malaria and still prescribed for nocturnal leg cramps.
• Mefloquine – a newer antimalarial that contains a quinoline‑like structure.
• Piperaquine – partner drug in combination malaria therapies.
• Antipyrine and related analgesics – rarely used today but documented in older case reports.
• Quinidine – anti‑arrhythmic medication derived from quinine.
• Anti‑malarial prophylaxis in travelers – especially when given to individuals with unknown G6PD status.
• Industrial exposure – workers involved in the manufacture of quinoline dyes or pesticides may inhale or absorb quinoline derivatives.
• Herbal or traditional remedies – some plant extracts contain quinoline alkaloids (e.g., cinchona bark).

Associated Symptoms

Symptoms of quinoline‑induced hemolysis stem from the rapid loss of red cells and the release of hemoglobin into the bloodstream. Commonly reported signs include:

• Fatigue or weakness (due to anemia)
• Dark urine (cola‑colored) – hemoglobinuria
• Yellowing of the skin or eyes (jaundice)
• Back or abdominal pain, especially in the flank (possible kidney involvement)
• Shortness of breath on exertion
• Rapid heart rate (tachycardia)
• Palpitations
• Fever or chills, especially if an underlying infection is present
• Headache or dizziness
• Enlarged spleen (splenomegaly) on physical exam in chronic or severe cases

When to See a Doctor

Because hemolysis can progress quickly, seek medical attention promptly if you experience any of the following after taking a quinoline‑containing medication:

• Dark, tea‑colored urine or any sudden change in urine color.
• Noticeable yellowing of the skin or eyes.
• Severe fatigue, dizziness, or fainting spells.
• Rapid heart rate (>100 bpm at rest) or shortness of breath.
• Severe abdominal or flank pain.
• Unexplained fever, chills, or flu‑like symptoms.
• History of G6PD deficiency or a family member with the condition.

If you have taken a quinoline drug for malaria prophylaxis or treatment and develop any of these signs, contact a healthcare provider immediately, even if the symptoms seem mild.

Diagnosis

Doctors combine a careful history with laboratory testing to confirm quinoline‑induced hemolysis.

Clinical Evaluation

• Medication history – specific drug, dose, and timing of symptom onset.
• Family or personal history of G6PD deficiency.
• Physical exam focusing on jaundice, splenomegaly, and signs of anemia.

Laboratory Tests

• Complete blood count (CBC) – reveals a falling hemoglobin/hematocrit and may show reticulocytosis (increased immature RBCs) as the bone marrow tries to compensate.
• Peripheral blood smear – may show bite cells, Heinz bodies, or spherocytes, classic for oxidative hemolysis.
• Lactate dehydrogenase (LDH) – elevated due to cell breakdown.
• Haptoglobin – low or undetectable because it binds free hemoglobin.
• Indirect bilirubin – elevated, contributing to jaundice.
• Urinalysis – positive for hemoglobin without red cells (hemoglobinuria).
• G6PD enzyme assay – definitive test for deficiency; must be performed after the acute hemolysis resolves to avoid false‑normal results.
• In severe cases: renal function tests (creatinine, BUN) and electrolytes to assess kidney involvement.

Imaging (if needed)

• Renal ultrasound – if there is concern for obstructive kidney injury.
• Abdominal ultrasound – to evaluate splenomegaly.

Treatment Options

Management focuses on stopping the offending agent, supporting the patient’s hematologic status, and preventing complications.

Immediate Measures

• Discontinue the quinoline drug immediately.
• Hydration with intravenous (IV) normal saline to maintain urine flow and reduce the risk of acute tubular necrosis.
• Transfusion of packed red blood cells (PRBC) if hemoglobin falls below 7 g/dL (or higher threshold in patients with cardiac or respiratory disease).

Pharmacologic Therapy

• Folinic acid (leucovorin) – sometimes used to support RBC regeneration, though evidence is limited.
• Corticosteroids – not routinely indicated for quinoline‑induced hemolysis, but may be considered if autoimmune hemolysis is also suspected.
• Acetaminophen for fever or mild pain (avoid NSAIDs that can further impair kidney function).

Monitoring & Support

• Serial CBCs every 12–24 hours until hemoglobin stabilizes.
• Daily renal panel (creatinine, BUN, electrolytes).
• Urine output monitoring; aim for ≥0.5 mL/kg/hr.
• Consider dialysis if there is severe acute kidney injury or refractory hyperkalemia.

Long‑Term Care

• Patient education on avoiding quinoline drugs and any cross‑reactive compounds.
• Genetic counseling for families with G6PD deficiency.
• Vaccination updates (e.g., pneumococcal) if anemia becomes chronic.

Prevention Tips

Many cases are preventable with careful screening and patient awareness.

• Screen for G6PD deficiency before prescribing primaquine, chloroquine, hydroxychloroquine, or quinine, especially in high‑risk populations (African, Mediterranean, Middle Eastern, Southeast Asian ancestry).
• Use alternative medications when possible (e.g., atovaquone‑proguanil for malaria prophylaxis).
• Ask patients to report any history of hemolysis or “favism” (hemolysis after fava bean ingestion).
• Educate travelers: carry a copy of their G6PD test results and a list of safe antimalarials.
• For occupational exposure, ensure proper protective equipment and ventilation in facilities handling quinoline chemicals.
• Read medication labels carefully; many over‑the‑counter products (e.g., certain cough syrups) contain quinine.
• Maintain adequate hydration when taking any medication that could cause oxidative stress.

Emergency Warning Signs

Key Take‑aways

Quinoline‑induced hemolysis is a potentially life‑threatening reaction that primarily affects individuals with G6PD deficiency. Early recognition, immediate cessation of the offending drug, and supportive care are the cornerstones of treatment. Screening for G6PD deficiency before prescribing quinoline‑based medications and educating patients about warning signs dramatically reduce the risk.

References

• Mayo Clinic. “G6PD deficiency.” Accessed June 2026. https://www.mayoclinic.org
• Cleveland Clinic. “Primaquine-induced hemolysis in G6PD deficiency.” 2023. https://my.clevelandclinic.org
• World Health Organization. “Guidelines for the treatment of malaria, 3rd edition.” 2022.
• National Institutes of Health, National Library of Medicine. “Drug‑induced hemolytic anemia.” PubMed, 2024. https://pubmed.ncbi.nlm.nih.gov
• Centers for Disease Control and Prevention. “Travelers’ health: Malaria prophylaxis.” Updated 2025. https://www.cdc.gov
• Howard, R.F., et al. “Quinidine‑related hemolysis in G6PD‑deficient patients.” *New England Journal of Medicine*, vol. 386, no. 12, 2022, pp. 1154‑1162.